Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
By S. de Sanjosé, W. Quint, L. Alemany, D. Geraets, J. Klaustermeier, B. Lloveras, S. Tous, A. Félix, L. Bravo, Hai-rim Shin and 41 more. The Lancet Oncology, 2010
2,506 citations recorded by the source corpus.
Subfields: Epidemiology, Microbiology, Obstetrics and Gynecology
View Paper: https://www.semanticscholar.org/paper/43f6a6c9cc360cdfc99148006a18c4d5968590ef
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Obstetrics and Gynecology
Citations in the corpus
- A review of clinical trials of human papillomavirus prophylactic vaccines. (2012, background): “Cross-protection against non-vaccine types is an important consideration since non-vaccine types are associated with approximately 30% of cervical cancers worldwide [6].”
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. (2012, positive): “HPV18 causes a greater proportion of glandular cancers, adenocarcinoma, and adenosquamous carcinoma than squamous cell carcinoma (approximately 32% vs 8%, respectively).(9) The establishment of the causal link between HPV and cervical cancer, along with an understanding of the epidemiology and natur”
- Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 (2021, neutral): “7%of cervical cancer cases worldwide [42].”